Finance

Lists
Why is GLUE down 3.03%?
Dive Deeper
GLUE:NASDAQ
Monte Rosa Therapeutics Inc
$8.64
-3.03%
(-0.27) 1D
$8.64
0.00% (0.00)
After hours
Closed: Nov 20, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GLUE...
Open
$8.73
High
$9.04
Low
$8.48
Mkt. cap
738.29M
Avg. vol.
1.41M
Volume
2.52M
52-wk high
$25.77
52-wk low
$8.48
EPS
-$1.38
Beta
1.41
Shares outstanding
85.45M
No. of employees
185
Open
$8.73
High
$9.04
Low
$8.48
Mkt. cap
738.29M
Avg. vol.
1.41M
Volume
2.52M
52-wk high
$25.77
52-wk low
$8.48
EPS
-$1.38
Beta
1.41
Shares outstanding
85.45M
No. of employees
185
News stories
From web sources and news partners
About Monte Rosa Therapeutics Inc
CEO-
Employees185
Founded2019
HeadquartersBoston, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Analyst ratings
Based on 8 analysts giving stock ratings to GLUE in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for GLUE in the last 3 months.
Highest
Current $8.64
$37.00 (+328.24%)
Average
$25.14 (+190.97%)
Lowest
$15.00 (+73.61%)
Analyst
Recommendation
Action
Price target
Projected
Date
Edward Tenthoff
Piper Sandler
Buy
Reiterated
$37.00
+328.2%
11/10/2026
Robert Driscoll
Wedbush
Buy
Reiterated
$27.00
+212.5%
11/06/2026
Unknown Analyst
Wedbush
Buy
Reiterated
$27.00
+212.5%
11/06/2026
Derek Archila
Wells Fargo
Buy
Reiterated
$25.00
+189.4%
11/06/2026
Michael Schmidt
Guggenheim
Buy
Maintained
$28.00
+224.1%
11/05/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$25.00
+189.4%
11/06/2026
Faisal Khurshid
Jefferies
Buy
Maintained
$15.00
+73.6%
11/05/2026
Unknown Analyst
UBS
Buy
Reiterated
$19.00
+119.9%
10/12/2026
Alice Nettleton
UBS
Buy
Initiated
$19.00
+119.9%
10/12/2026
Oliver McCammon
LifeSci Capital
Buy
Maintained
-
-
10/02/2026
Brian Cheng
J.P. Morgan
Buy
Maintained
$27.00
+212.5%
08/10/2026
Marc Frahm
TD Cowen
Buy
Reiterated
-
-
05/07/2026
Last report
Nov 5, 2026
Fiscal period
Q3 2026
$0.03 / -$0.20
+114.90%beat
Revenue / Est. (USD)
54.37M / 33.89M
+60.42%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
2.78M
4.21M
8.97M
54.37M
Cost of goods sold
39.89M
41.82M
45.99M
43.27M
Cost of revenue
39.89M
41.82M
45.99M
43.27M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
12.60M
12.42M
12.11M
13.03M
Operating expense
12.60M
12.42M
12.11M
13.03M
Total operating expenses
52.50M
54.24M
58.10M
56.30M
Operating income
-49.72M
-50.03M
-49.13M
-1.94M
Other non operating income
-
-
-
-
EBT including unusual items
-46.08M
-44.45M
-43.19M
3.78M
EBT excluding unusual items
-46.08M
-44.45M
-43.19M
3.78M
Income tax expense
59.00K
52.00K
208.00K
716.00K
Effective tax rate
-0.13%
-0.12%
-0.48%
18.95%
Other operating expenses
-
-
-
-
Net income
-46.14M
-44.50M
-43.40M
3.06M
Net profit margin
-1,658.94%
-1,057.08%
-483.91%
5.63%
Earnings per share
-0.55
-0.45
-0.43
0.03
Interest and investment income
3.69M
5.59M
5.92M
5.62M
Interest expense
-
-
-
-
Net interest expenses
3.69M
5.59M
5.92M
5.62M
Depreciation and amortization charges
-
-
-
-
EBITDA
-47.63M
-48.00M
-47.22M
205.00K
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps